Inventus Announces Bulk Sample Processing Underway and Provides Drill Program Update

Inventus Announces Bulk Sample Processing Underway and Provides Drill Program Update GlobeNewswire November 06, 2025 TORONTO, Nov. 06, 2025 (GLOBE NEWSWIRE) — Inventus Mining Corp. (TSXV: IVS) (“Inventus” or the “Company”) is pleased to announce that processing of the 007 North bulk sample from its wholly-owned Pardo Gold Project, located 65 km northeast of Sudbury, […]

Noema Pharma Announces Phase 2a Study Results with Cendifensine in Women with Vasomotor Symptoms (Hot Flashes) Due to Menopause

Noema Pharma Announces Phase 2a Study Results with Cendifensine in Women with Vasomotor Symptoms (Hot Flashes) Due to Menopause Cendifensine demonstrates 92% reduction in number of hot flashes GlobeNewswire November 06, 2025 BASEL, Switzerland and BOSTON, Nov. 06, 2025 (GLOBE NEWSWIRE) — Noema Pharma AG today announced positive topline results from a Phase 2a, open-label

Tenax Therapeutics to Host Virtual KOL Call to Discuss TNX-103 (Oral Levosimendan) for the Treatment of PH-HFpEF

Tenax Therapeutics to Host Virtual KOL Call to Discuss TNX-103 (Oral Levosimendan) for the Treatment of PH-HFpEF GlobeNewswire November 06, 2025 CHAPEL HILL, N.C., Nov. 06, 2025 (GLOBE NEWSWIRE) — Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, today

Accipiter Biosciences Emerges from Stealth with $12.7 Million in Seed Financing to Deliver de novo Protein Therapies for Complex Diseases

Accipiter Biosciences Emerges from Stealth with $12.7 Million in Seed Financing to Deliver de novo Protein Therapies for Complex Diseases GlobeNewswire November 06, 2025 Strong syndicate of investors co-led by Takeda and Flying Fish Partners Proceeds will advance preclinical programs in immunology and oncology Strategic partnerships established with Pfizer and Kite Pharma, a Gilead Company,

KVH Industries Reports Third Quarter 2025 Results

KVH Industries Reports Third Quarter 2025 Results GlobeNewswire November 06, 2025 MIDDLETOWN, R.I., Nov. 06, 2025 (GLOBE NEWSWIRE) — KVH Industries, Inc. (Nasdaq: KVHI), reported financial results for the quarter ended September 30, 2025 today. The company will hold a conference call to discuss these results at 9:00 a.m. ET today, which can be accessed

Datadog Announces Third Quarter 2025 Financial Results

Datadog Announces Third Quarter 2025 Financial Results GlobeNewswire November 06, 2025 Third quarter revenue grew 28% year-over-year to $886 million Robust growth of larger customers, with about 4,060 $100k+ ARR customers, up from about 3,490 a year ago Reached a milestone of over 1,000 integrations on the Datadog unified platform NEW YORK, Nov. 06, 2025

Playboy and Hefner Capital Announce Creative Partnership to Produce Feature Film DEAD AFTER DARK

Playboy and Hefner Capital Announce Creative Partnership to Produce Feature Film DEAD AFTER DARK GlobeNewswire November 06, 2025 LOS ANGELES, Nov. 06, 2025 (GLOBE NEWSWIRE) — Playboy, Inc. (NASDAQ: PLBY) (the “Company” or “Playboy”) and Hefner Capital today announced a new creative partnership to produce Dead After Dark, an original feature film currently in development.

Apyx Medical Corporation Reports Third Quarter 2025 Financial Results

Apyx Medical Corporation Reports Third Quarter 2025 Financial Results GlobeNewswire November 06, 2025 Initiated full U.S. commercial launch of AYON Body Contouring System(TM) (AYON) at end of Q3 2025, with demand for pre-orders exceeding expectations Submitted new 510(k) for AYON for device label expansion to include power liposuction Increased total revenue guidance for FY2025 to

Medicenna and Fondazione Melanoma Onlus Collaborate to Advance MDNA11 Before First-Line Therapy in a Randomized Neoadjuvant Combination Trial, “NEO-CYT”, in High-Risk, Surgically Resectable Stage III Melanoma

Medicenna and Fondazione Melanoma Onlus Collaborate to Advance MDNA11 Before First-Line Therapy in a Randomized Neoadjuvant Combination Trial, “NEO-CYT”, in High-Risk, Surgically Resectable Stage III Melanoma GlobeNewswire November 06, 2025 NEO-CYT is a randomized, multi-centre trial of neoadjuvant MDNA11 (before curative intent surgery) sponsored by the Fondazione Melanoma Onlus, and led by Professor Paolo A.

Baker Hughes Secures Additional Order for Rio Grande LNG Expansion

Baker Hughes Secures Additional Order for Rio Grande LNG Expansion GlobeNewswire November 06, 2025 Award from Bechtel includes supply of the primary liquefaction equipment for NextDecade's Rio Grande LNG Train 5 Order includes Frame 7 gas turbines and centrifugal compressors, replicating proven solutions from previous trains Technology will enable an additional LNG production capacity of

Scroll to Top